ISB News

2017 Consilience Event

ISB hosts its annual Consilience event on May 19 at 1pm. The theme is “Integrating Diverse Approaches to Communicating the Complexities of Science.” This year’s speakers include Dan Goods and David Delgado from NASA’s Jet Propulsion Laboratory, and Afroditi Psarra from University of Washington. ISB co-founder Dr. Lee Hood will give opening remarks. Featured artist Ginny Ruffner will present her interactive augmented reality installation “Poetic Hybrids.” The goal of the Consilience program is to enrich the culture of ISB, and its affiliated networks, by featuring professionals who break barriers and work at the intersections of the humanities and sciences. The event is free and open to the public. Register and learn more at the link below.

Learn more

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.